Keywords
breast - metastases - fallopian tube - cancer
Case Presentation
A 64-year-old female presented with 3 months onset of right-sided pelvic pain. Pelvic
ultrasound showed a right adnexal mass ([Fig. 1]), with the right ovary not identified separately. Magnetic resonance imaging of
pelvis ([Figs. 2] and [3]) revealed that the right adnexal mass was external iliac chain nodal mass. Both
ovaries were atrophic. CA 125 tumor marker was elevated, measuring 203 units/mL. Right
iliac node biopsy demonstrated metastatic poorly differentiated adenocarcinoma of
Mullerian primary.
Fig. 1 Transvaginal pelvic ultrasound demonstrated a solid hypoechoic right adnexal mass
measuring approximately 2.6 × 3.9 × 3.3 cm. Right ovary was not seen separately from
the mass.
Figs. 2, 3 Magnetic resonance imaging pelvis ([Fig. 2]—axial T2-weighted image and [Fig. 3]—axial post-contrast venous phase image) demonstrated right external iliac chain
nodal masses (blue arrow), largest measuring 3.3 × 2.8 × 5.1 cm. Both ovaries were
atrophic.
Subsequently, hysterectomy, bilateral salpingo-oophorectomy, and pelvic node dissection
was performed, and surgical pathology demonstrated high-grade serous carcinoma in
both fallopian tubes and pelvic nodes. The tumor cells were immunoreactive for CK7,
PAX8, P53, WT1, and P16 supporting serous carcinoma ([Fig. 4]). The presence of serous intraepithelial carcinoma and tubal involvement supported
fallopian tube origin.
Fig. 4 Medium-power view (A) and high-power view (B) of serous carcinoma of the fallopian tube. WT1 immunostain demonstrates nuclear
immunoreactivity in the tumor cells (C).
18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT)
for staging demonstrated FDG avid enlarged right external iliac, and peri-aortic nodes.
A 1 cm FDG avid posteromedial left breast mass was also noted ([Figs. 5] and [6]).
Figs. 5, 6
18F-fluorodeoxyglucose positron emission tomography-computed tomography study demonstrated
fluorodeoxyglucose avid 1 cm posteromedial left breast mass (red circle).
Fig. 7 Targeted left breast ultrasound demonstrated a hypoechoic solid mass with indistinct
margins, measuring 0.8 × 0.9 × 1.1 cm, at 7:00, 5 cm from the nipple.
Diagnostic mammogram did not demonstrate the breast mass due to its far posterior
location. Targeted breast ultrasound demonstrated a 1.1 cm hypoechoic left breast
mass with indistinct margins at 7 o' clock, 5 cm from the nipple ([Fig. 7]), Breast Imaging Reporting And Data System: 4, suspicious, with recommendation for
biopsy. Ultrasound-guided biopsy of the breast mass ([Figs. 8] and [9]) revealed metastatic poorly differentiated carcinoma of primary Mullerian origin
involving a lymph node, with tumor profile positive for WT1, and PAX8 ([Fig. 10]). Since initiating chemotherapy, 18F-FDG PET/CT has shown decrease in size and FDG avidity of all nodes, including resolution
of FDG avidity in the breast mass ([Fig. 11]).
Figs. 8, 9 Ultrasound-guided left breast biopsy of the suspicious mass at 7:00, 5 cm from the
nipple performed ([Fig. 8]) with appropriate placement of HydroMark clip ([Fig. 9]).
Fig. 10 Low power (A) and high power (B) views of breast biopsy specimen demonstrate high-grade metastatic serous carcinoma
involving lymphoid tissue. PAX8 (C) and WT1 (D) immunostains demonstrate nuclear immunoreactivity, supporting tubal origin.
Fig. 11 Post-chemotherapy 18F-fluorodeoxyglucose positron emission tomography-computed tomography study demonstrates
the posteromedial left breast mass with a biopsy clip (red circle) and without any
fluorodeoxyglucose uptake.
Discussion
Primary fallopian tube carcinoma (PFTC) is rare, representing around 1% of gynecologic
malignancies.[1] In 2014, revised International Federation of Gynecology and Obstetrics staging incorporated
ovarian, fallopian tube, and peritoneal cancers into a common group, called “Mullerian
carcinomas,” due to considerable overlap in origin and histology. Metastases of these
Mullerian carcinomas commonly go to the peritoneal cavity, inguinal, and para-aortic
nodes[2] with breast metastases being extremely rare.[3]
[4]
[5] From review of literature, our case is the fourth documented case of breast metastasis
from PFTC, with previous cases reported by Fishman et al in 1994, Papakonstatinou
et al in 2009, and Buyukkurt et al also in 2009.[3]
[6]
[7] All reported cases of PFTC with breast metastasis vary in their presentation, with
the unifying factor being advanced stage at diagnosis.
Nonmammary metastasis to the breast is rare. It is important to differentiate primary
breast cancer and breast metastasis presenting as a solitary breast mass, due to significant
implications on treatment and prognosis. On imaging, breast metastases present as
single or multiple round masses with circumscribed margins.[8] The final diagnosis depends on immunohistochemical results. Mullerian carcinomas
are positive for PAX8 and WT1 for both primary tumor and metastasis.[8]
Conclusion
Our case highlights that breast metastasis remains an important differential in a
patient with known primary cancer and a breast mass. Atypical cancer metastases, including
breast metastasis from Mullerian cancers, may be encountered more frequently, due
to prolonged survival and advances in imaging and treatment. It is, therefore, important
to document and share unique presentations of these metastatic Mullerian cancers.
